Genetic target validation studies have demonstrated that the apoptosis signal-regulating kinase 1 (ASK1) represents an important target for the treatment of rheumatoid arthritis, cardiac diseases, and several neurodegenerative disorders. To identify small-molecule inhibitors of ASK1, we have developed a high-throughput screening-compatible, homogenous, biochemical assay using AlphaScreen technology. This novel assay design utilizes purified stress-activated ASK1 signalosome complex, and it monitors phosphorylation of its full-length native substrate, MKK6. The assay has been optimized in a 384-well format and validated by screening the Sigma LOPAC library. The results presented here demonstrate that the assay is sensitive and robust with a Z′ factor value of 0.88±0.04 and a signal-to-background ratio of 11, indicating that this assay can be used to screen large chemical libraries to discover novel inhibitors of ASK1.
Get full access to this article
View all access options for this article.
References
1.
MatsukawaJ, MatsuzawaA, TakedaK, IchijoH: The ASK1-MAP kinase cascades in mammalian stress response. J Biochem, 2004; 136:261–265.
2.
NoguchiT, TakedaK, MatsuzawaA, et al.: Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem, 2005; 280:37033–37040.
3.
TobiumeK, SaitohM, IchijoH: Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol, 2002; 191:95–104.
4.
ChenZ, SeimiyaH, NaitoM, et al.: ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene, 1999; 18:173–180.
5.
IchijoH, NishidaE, IrieK, et al.: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 1997; 275:90–94.
6.
McDonaldPH, ChowCW, MillerWE, et al.: Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science, 2000; 290:1574–1577.
7.
FaigleR, BrederlauA, ElmiM, et al.: ASK1 inhibits astroglial development via p38 mitogen-activated protein kinase and promotes neuronal differentiation in adult hippocampus-derived progenitor cells. Mol Cell Biol, 2004; 24:280–293.
8.
MatsuzawaA, SaegusaK, NoguchiT, et al.: ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol, 2005; 6:587–592.
GalvanV, BanwaitS, SpilmanP, et al.: Interaction of ASK1 and the beta-amyloid precursor protein in a stress-signaling complex. Neurobiol Dis, 2007; 28:65–75.
11.
SaitohM, NishitohH, FujiiM, et al.: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J, 1998; 17:2596–2606.
SubramanianRR, ZhangH, WangH, IchijoH, MiyashitaT, FuH: Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14–3-3 proteins. Exp Cell Res, 2004; 294:581–591.
14.
SturchlerE, FeursteinD, ChenW, McDonaldP, DuckettD: Stress-induced nuclear import of apoptosis signal-regulating kinase 1 is mediated by karyopherin alpha2/beta1 heterodimer. Biochim Biophys Acta, 2013; 1833:583–592.
15.
TobiumeK, MatsuzawaA, TakahashiT, et al.: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep, 2001; 2:222–228.
16.
VolynetsGP, ChekanovMO, SynyuginAR, et al.: Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). J Med Chem, 2011; 54:2680–2686.
17.
OkamotoM, SaitoN, KojimaH, et al.: Identification of novel ASK1 inhibitors using virtual screening. Bioorg Med Chem, 2011; 19:486–489.
18.
ZhangJH, ChungTD, OldenburgKR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen, 1999; 4:67–73.
19.
O'BrianCA, WardNE: Staurosporine: a prototype of a novel class of inhibitors of tumor cell invasion?. J Natl Cancer Inst, 1990; 82:1734–1735.
20.
ReedGF, LynnF, MeadeBD: Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol, 2002; 9:1235–1239.
21.
HodderP, CassadayJ, PeltierR, et al.: Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system. Anal Biochem, 2003; 313:246–254.
22.
SturchlerE, FeursteinD, McDonaldP, DuckettD: ASK1 and Its Role in Neurodegenerative Diseases. In: Neurodegenerative Diseases—Processes, Prevention, Protection and Monitoring. ChangRCC (ed.), InTech, Croatia, 2011.
23.
TakekawaM, TatebayashiK, SaitoH: Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell, 2005; 18:295–306.
24.
BennettBL, SasakiDT, MurrayBW, et al.: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA, 2001; 98:13681–13686.
25.
HoesselR, LeclercS, EndicottJA, et al.: Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol, 1999; 1:60–67.
26.
LeclercS, GarnierM, HoesselR, et al.: Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J Biol Chem, 2001; 276:251–260.
27.
SkidmoreAF, BeebeeTJ: Characterization and use of the potent ribonuclease inhibitor aurintricarboxylic acid for the isolation of RNA from animal tissues. Biochem J, 1989; 263:73–80.
28.
KumamotoT, FujiiM, HouDX: Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem, 2009; 332:33–41.
29.
WalkerEH, PacoldME, PerisicO, et al.: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell, 2000; 6:909–919.
